MGI Saforis NDA To Be Based On Single Phase III Trial; Filing Planned For Q3
MGI Pharma expects to file an NDA for Saforis (l-glutamine oral suspension) for the treatment of oral mucositis based on the results of one Phase III trial and supportive earlier-phase trials
You may also be interested in...
MGI will highlight the efficacy profile of its myelodysplastic syndromes therapy Dacogen when detailing decitabine to oncologists
MGI Pharma's anti-emetic Aloxi (palonosetron) gained market share in the first month of average sales price-based reimbursement despite a drop in prescription volume for the class
Amgen will launch the oral mucositis treatment Kepivance (palifermin) in late January following FDA approval Dec. 15